157 related articles for article (PubMed ID: 36958430)
1. CD73 in glioblastoma: Where are we now and what are the future directions?
Gelsleichter NE; Azambuja JH; Rubenich DS; Braganhol E
Immunol Lett; 2023; 256-257():20-27. PubMed ID: 36958430
[TBL] [Abstract][Full Text] [Related]
2. CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A
Yan A; Joachims ML; Thompson LF; Miller AD; Canoll PD; Bynoe MS
J Neurosci; 2019 May; 39(22):4387-4402. PubMed ID: 30926752
[TBL] [Abstract][Full Text] [Related]
3. Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.
Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Iser IC; Lenz GS; de Oliveira FH; Venturin G; Greggio S; daCosta JC; Wink MR; Sevigny J; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
Mol Neurobiol; 2020 Feb; 57(2):635-649. PubMed ID: 31407144
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
Figueiró F; de Oliveira CP; Bergamin LS; Rockenbach L; Mendes FB; Jandrey EH; Moritz CE; Pettenuzzo LF; Sévigny J; Guterres SS; Pohlmann AR; Battastini AM
Purinergic Signal; 2016 Jun; 12(2):303-12. PubMed ID: 26910734
[TBL] [Abstract][Full Text] [Related]
5. CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.
Azambuja JH; Gelsleichter NE; Beckenkamp LR; Iser IC; Fernandes MC; Figueiró F; Battastini AMO; Scholl JN; de Oliveira FH; Spanevello RM; Sévigny J; Wink MR; Stefani MA; Teixeira HF; Braganhol E
Mol Neurobiol; 2019 May; 56(5):3260-3279. PubMed ID: 30117104
[TBL] [Abstract][Full Text] [Related]
6. An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach.
Arab S; Hasannejad F
Clin Transl Oncol; 2022 May; 24(5):742-756. PubMed ID: 34792724
[TBL] [Abstract][Full Text] [Related]
7. Blockade of CD73 delays glioblastoma growth by modulating the immune environment.
Azambuja JH; Schuh RS; Michels LR; Iser IC; Beckenkamp LR; Roliano GG; Lenz GS; Scholl JN; Sévigny J; Wink MR; Stefani MA; Battastini AMO; Figueiró F; Teixeira HF; Braganhol E
Cancer Immunol Immunother; 2020 Sep; 69(9):1801-1812. PubMed ID: 32350590
[TBL] [Abstract][Full Text] [Related]
8. Small molecular CD73 inhibitors: Recent progress and future perspectives.
Ge GH; Wang QY; Zhang ZH; Zhang X; Guo S; Zhang TJ; Meng FH
Eur J Med Chem; 2024 Jan; 264():116028. PubMed ID: 38086190
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
[TBL] [Abstract][Full Text] [Related]
10. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
[TBL] [Abstract][Full Text] [Related]
11. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
12. Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays.
Allard B; Cousineau I; Spring K; Stagg J
Methods Enzymol; 2019; 629():269-289. PubMed ID: 31727245
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
de Leve S; Wirsdörfer F; Jendrossek V
Front Immunol; 2019; 10():698. PubMed ID: 31024543
[TBL] [Abstract][Full Text] [Related]
14. Advances in CD73 inhibitors for immunotherapy: Antibodies, synthetic small molecule compounds, and natural compounds.
Zhang M; Dai X; Xiang Y; Xie L; Sun M; Shi J
Eur J Med Chem; 2023 Oct; 258():115546. PubMed ID: 37302340
[TBL] [Abstract][Full Text] [Related]
15. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Lenz GS; de Oliveira FH; Wink MR; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1177-1182. PubMed ID: 32417936
[TBL] [Abstract][Full Text] [Related]
16. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
[TBL] [Abstract][Full Text] [Related]
17. Involvement of ecto-5'-nucleotidase/CD73 in U138MG glioma cell adhesion.
Cappellari AR; Vasques GJ; Bavaresco L; Braganhol E; Battastini AM
Mol Cell Biochem; 2012 Jan; 359(1-2):315-22. PubMed ID: 21858682
[TBL] [Abstract][Full Text] [Related]
18. Influence of NSAIDs and methotrexate on CD73 expression and glioma cell growth.
Lopes DV; de Fraga Dias A; Silva LFL; Scholl JN; Sévigny J; Battastini AMO; Figueiró F
Purinergic Signal; 2021 Jun; 17(2):273-284. PubMed ID: 33745072
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner.
Tang T; Huang X; Lu M; Zhang G; Han X; Liang T
Nat Commun; 2023 Jun; 14(1):3364. PubMed ID: 37291128
[TBL] [Abstract][Full Text] [Related]
20. Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production.
Du X; Moore J; Blank BR; Eksterowicz J; Sutimantanapi D; Yuen N; Metzger T; Chan B; Huang T; Chen X; Chen Y; Duong F; Kong W; Chang JH; Sun J; Zavorotinskaya T; Ye Q; Junttila MR; Ndubaku C; Friedman LS; Fantin VR; Sun D
J Med Chem; 2020 Sep; 63(18):10433-10459. PubMed ID: 32865411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
